drugset
drugset / Trial / NCT00053963

FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia

NCT00053963 ↗

Phase 1 Completed 30 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of FR901228 in treating children with refractory or recurrent solid tumors or leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die

Timeline

Start
2002-09
Primary completion
2006-02
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Romidepsin Peptide — Intravenous

Indications

B-cell chronic lymphocytic leukemia blast phase chronic myelogenous leukemia, BCR-ABL1 positive childhood acute lymphoblastic leukemia childhood acute myeloid leukemia childhood brain stem glioma childhood central nervous system germ cell tumor childhood central nervous system primitive neuroectodermal neoplasm childhood cerebellar astrocytic neoplasm childhood cerebral astrocytoma childhood choroid plexus neoplasm childhood medulloblastoma childhood spinal cord tumor craniopharyngioma grade II meningioma grade III meningioma low-grade astrocytoma pediatric infratentorial ependymoma pediatric supratentorial ependymoma